Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept

Journal of the American Academy of Dermatology

Volumn 63, Issue 2, 2010, Pages 228-234

  Bissonnette, Robert ^a   Bolduc, Chantal ^a   Poulin, Yves ^b   Guenther, Lyn ^c   Lynde, Charles W ^d   Maari, Catherine ^a  

^a INNOVADERM RESEARCH   (Canada)

^b Centre Dermatologique du Québec Métropolitain   (Canada)

^c Guenther Dermatology Research Centre   (Canada)

^d Lynderm Research Inc Canada   (Canada)

Author keywords

adalimumab; anti tumor necrosis factor alfa; etanercept; psoriasis

Indexed keywords

ADALIMUMAB; ETANERCEPT; YELLOW FEVER VACCINE; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BRONCHITIS; CLINICAL EVALUATION; CLINICAL TRIAL; COMMON COLD; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; HUMAN; INFECTION; INJECTION SITE REACTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; OPEN STUDY; PATIENT SATISFACTION; PHYSICIAN; PRIORITY JOURNAL; PSORIASIS VULGARIS; SCORING SYSTEM; SINUSITIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; YELLOW FEVER; BODY SURFACE; DRUG ANTAGONISM; DRUG RESISTANCE; HOSPITALIZATION; MIDDLE AGED; PATHOLOGY; PSORIASIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BODY SURFACE AREA; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77955289945     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.08.040     Document Type: Article

References (13)

1. C.L. Leonardi, K.A. Papp, K.B. Gordon, A. Menter, S.R. Feldman, and I. Caro et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial J Am Acad Dermatol 52 2005 425 433
2. R. Bissonnette Etanercept for the treatment of psoriasis Skin Therapy Lett 11 2006 1 4
3. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang et al. Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
4. K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, and A.M. Nakanishi et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312
5. A. Menter, S. Tyring, K. Gordon, A. Kimball, C. Leonardi, and R. Langley et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115
6. Report of the Dermatologic and Opthalmic Drugs Advisory Committee 49th meeting, open session. Gaithersburg, Md: US Food and Drug Administration; March 1998. Available at: http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3402t2.rtf. Accessed October 21, 2009.
7. L. Guenther, R.G. Langley, N.H. Shear, R. Bissonnette, V. Ho, and C. Lynde et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian psoriasis expert panel J Cutan Med Surg 8 2004 321 337
8. R.G. Langley, V. Ho, C. Lynde, K.A. Papp, Y. Poulin, and N. Shear Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches J Cutan Med Surg 9 suppl 2006 18 25 (Pubitemid 44244081)
9. A. Menter, A. Gotleib, S.R. Feldman, A.S. Van Vorhees, C.L. Leonard, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1; overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850 (Pubitemid 351509656)
10. J. Saurat, G. Stingl, L. Dubertret, K. Papp, R. Langley, and J. Ortonne et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566
11. K. Haitz, and R. Kalb Infliximab in the treatment of psoriasis in patients previously treated with etanercept J Am Acad Dermatol 57 2007 120 125
12. M. Papoutsaki, M.-S. Chimenti, A. Costanzo, M. Talamonti, A. Zangrilli, and A. Giunta Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics J Am Acad Dermatol 57 2007 269 275 (Pubitemid 47048857)
13. L. Yip, S. Harrison, and P. Foley From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis Australas J Dermatol 49 2008 152 155 (Pubitemid 352000516)